FDA Panels Will Meet March 20 To Mull Second OTC Naloxone Application

A group of FDA advisers will meet March 20 to discuss Harm Reduction Therapeutics’ proposed over-the-counter naloxone nasal spray, which was granted priority review by the agency in December, coming as the Biden administration pushes to increase access to and affordability of the overdose reversal drug as part of its broader strategy to address the opioid overdose epidemic. During the meeting, members of FDA’s Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee will discuss Harm...